StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Rajesh Satpute

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byRajesh SatputeHorizon: NA (inferred Intraday)26 Oct 2026, 9:25 am ISTvia CNBC Awaaz.

Entry₹1,272Inferred
Target₹1,300
Total upside +2.20% (call closed)
Stop loss₹1,235-2.91% risk
Exit₹1,300Target hit — time not yet verified
Target hit+2.20%0.00%upside left
Follow Rajesh Satpute for new calls(8% target hit, 124 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 14 active Intraday picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 2:41 pm IST
4 supporting1 neutral2 opposing
Supports the BUY call (4)

8 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·26 Oct · today

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 5d ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 5d ago

(opens in new tab)

Dr. Reddy's Laboratories received approval from the DCGI for Zytorvi (toripalimab) in combination with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma in India.

BSE · Company Update·21 Oct · 5d ago

(opens in new tab)
Neutral / worth noting (1)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·23 Oct · 2d ago

(opens in new tab)
Weighs against the BUY call (2)

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 2d ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 2d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Rajesh Satpute

Every call and its outcome